Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma.

ABSTRACT:

Purpose

Patients with stage II and resected stage III melanomas have variable clinical outcomes, providing evidence of underlying biological differences in tumors and/or the patients themselves, beyond stage. The approval of adjuvant immunotherapy for stage IIB/C and resected stage III/IV disease (and adjuvant targeted therapy for resected stage III disease) has created a pressing need to develop biomarkers to accurately distinguish patients at low risk versus high risk for recurrence and death from melanoma. miRNAs are promising biomarkers because of their stability in tissues and fluids and their demonstrated functional and prognostic roles in melanoma. We hypothesized that miRNA expression could be integrated into prognostic models that would classify 5-year survival outcomes mo

SUBMITTER: Wiggins JM 

PROVIDER: S-EPMC12588674 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature